• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.

作者信息

Kelly K R, Espitia C M, Zhao W, Wu K, Visconte V, Anwer F, Calton C M, Carew J S, Nawrocki S T

机构信息

Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

出版信息

Leukemia. 2018 Jan;32(1):230-233. doi: 10.1038/leu.2017.272. Epub 2017 Aug 23.

DOI:10.1038/leu.2017.272
PMID:28832023
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5844271/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe7/5844271/5f768cd4b9a5/nihms900336f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe7/5844271/dce62ca88dbe/nihms900336f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe7/5844271/5f768cd4b9a5/nihms900336f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe7/5844271/dce62ca88dbe/nihms900336f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8fe7/5844271/5f768cd4b9a5/nihms900336f2.jpg

相似文献

1
Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy.溶瘤呼肠孤病毒使多发性骨髓瘤细胞对抗程序性死亡配体1（anti-PD-L1）治疗敏感。
Leukemia. 2018 Jan;32(1):230-233. doi: 10.1038/leu.2017.272. Epub 2017 Aug 23.
2
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.呼肠孤病毒诱导的细胞免疫治疗多发性骨髓瘤在耐药骨髓微环境中的作用。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001803.
3
Oncolytic virotherapy for multiple myeloma.多发性骨髓瘤的溶瘤病毒疗法
Expert Opin Biol Ther. 2008 Apr;8(4):463-73. doi: 10.1517/14712598.8.4.463.
4
Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.骨髓瘤 B7-H1（PD-L1）与 PD-1 结合诱导的骨髓瘤耐药性。
Cancer Immunol Res. 2016 Sep 2;4(9):779-88. doi: 10.1158/2326-6066.CIR-15-0296. Epub 2016 Jul 20.
5
A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.一种经PD-L1单链抗体片段改造的新型溶瘤病毒在小鼠模型中有效抑制肿瘤生长。
Cell Mol Immunol. 2019 Sep;16(9):780-782. doi: 10.1038/s41423-019-0264-7. Epub 2019 Jul 30.
6
Reovirus as a viable therapeutic option for the treatment of multiple myeloma.呼肠孤病毒作为多发性骨髓瘤治疗的一种可行的治疗选择。
Clin Cancer Res. 2012 Sep 15;18(18):4962-72. doi: 10.1158/1078-0432.CCR-11-3085. Epub 2012 Jul 3.
7
Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade.多发性骨髓瘤的免疫抑制作用被 PD-L1 阻断克服。
Biol Blood Marrow Transplant. 2011 Aug;17(8):1133-45. doi: 10.1016/j.bbmt.2011.03.011. Epub 2011 Apr 12.
8
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.来那度胺增强免疫检查点阻断诱导的多发性骨髓瘤免疫反应。
Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15.
9
The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.在一项1期研究中，PD - 1抑制剂用于多发性骨髓瘤的免疫检查点阻断治疗失败。
Leukemia. 2015 Jul;29(7):1621-2. doi: 10.1038/leu.2015.104. Epub 2015 May 19.
10
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.表达PD-L1微型抗体的武装溶瘤腺病毒增强嵌合抗原受体T细胞在实体瘤中的抗肿瘤作用。
Cancer Res. 2017 Apr 15;77(8):2040-2051. doi: 10.1158/0008-5472.CAN-16-1577. Epub 2017 Feb 24.

引用本文的文献

1
Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack.溶瘤免疫病毒疗法：在抗病毒的干草堆中寻找肿瘤抗原这根针。
Immunotherapy. 2025 Jun;17(8):585-594. doi: 10.1080/1750743X.2025.2513853. Epub 2025 Jun 6.
2
Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.用于个性化治疗和提高疗效的革命性癌症疗法：克服免疫检查点抑制剂疗法耐药性的策略
Cancers (Basel). 2025 Mar 4;17(5):880. doi: 10.3390/cancers17050880.
3
REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity.

本文引用的文献

1
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.纳武利尤单抗治疗复发或难治性血液系统恶性肿瘤患者：Ib期研究的初步结果
J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.
2
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.连接黏附分子A在晚期多发性骨髓瘤中过表达，并决定对溶瘤呼肠孤病毒的反应。
Oncotarget. 2015 Dec 1;6(38):41275-89. doi: 10.18632/oncotarget.5753.
3
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
REDD1是肾癌细胞对自噬抑制敏感性的一个决定因素，可通过靶向PIM活性进行治疗性利用。
Cancer Lett. 2025 Mar 31;613:217496. doi: 10.1016/j.canlet.2025.217496. Epub 2025 Jan 30.
4
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.蛋白酶体抑制可增强溶瘤呼肠孤病毒对多发性骨髓瘤的治疗作用，且与其直接细胞毒性作用无关。
J Hematol Oncol. 2025 Jan 20;18(1):1. doi: 10.1186/s13045-024-01645-3.
5
Virus nanotechnology for intratumoural immunotherapy.用于肿瘤内免疫治疗的病毒纳米技术。
Nat Rev Bioeng. 2024 Nov;2(11):916-929. doi: 10.1038/s44222-024-00231-z. Epub 2024 Sep 23.
6
Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients.溶瘤病毒：多发性骨髓瘤患者潜在的免疫治疗突破。
Front Immunol. 2024 Oct 30;15:1483806. doi: 10.3389/fimmu.2024.1483806. eCollection 2024.
7
Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors.溶瘤病毒在 CAR-T 细胞治疗实体瘤中的可靠佐剂作用。
Int J Mol Sci. 2024 Oct 16;25(20):11127. doi: 10.3390/ijms252011127.
8
DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.DNp73 通过靶向 MYC 和 MYCN 通路增强多发性骨髓瘤的肿瘤进展和免疫逃逸。
Front Immunol. 2024 Sep 24;15:1470328. doi: 10.3389/fimmu.2024.1470328. eCollection 2024.
9
Enhanced Anti-Tumor Response Elicited by a Novel Oncolytic Pseudorabies Virus Engineered with a PD-L1 Inhibitor.新型携带 PD-L1 抑制剂的溶瘤伪狂犬病病毒引发的增强抗肿瘤反应。
Viruses. 2024 Jul 31;16(8):1228. doi: 10.3390/v16081228.
10
Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.巨头联盟：CAR-T 细胞疗法与溶瘤病毒联合策略治疗血液系统恶性肿瘤。
Ann Hematol. 2024 Aug;103(8):2569-2589. doi: 10.1007/s00277-023-05488-9. Epub 2023 Oct 18.
来那度胺增强免疫检查点阻断诱导的多发性骨髓瘤免疫反应。
Clin Cancer Res. 2015 Oct 15;21(20):4607-18. doi: 10.1158/1078-0432.CCR-15-0200. Epub 2015 May 15.
4
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
5
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.靶向浆细胞样树突状细胞与T细胞、自然杀伤细胞和多发性骨髓瘤细胞相互作用中的PD1-PDL1免疫检查点。
Leukemia. 2015 Jun;29(6):1441-4. doi: 10.1038/leu.2015.11. Epub 2015 Jan 30.
6
PD-1 blockade induces responses by inhibiting adaptive immune resistance.程序性死亡受体1（PD-1）阻断通过抑制适应性免疫抵抗来诱导反应。
Nature. 2014 Nov 27;515(7528):568-71. doi: 10.1038/nature13954.
7
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.复发多发性骨髓瘤患者使用单药瑞欧溶素的I期试验。
Clin Cancer Res. 2014 Dec 1;20(23):5946-55. doi: 10.1158/1078-0432.CCR-14-1404. Epub 2014 Oct 7.
8
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.骨髓基质细胞诱导骨髓瘤细胞表达 B7-H1，从而在多发性骨髓瘤中产生侵袭性特征。
Leukemia. 2013 Feb;27(2):464-72. doi: 10.1038/leu.2012.213. Epub 2012 Jul 25.
9
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
10
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.呼肠孤病毒疗法可刺激内质网应激，诱导 NOXA 表达，并增强硼替佐米介导的多发性骨髓瘤细胞凋亡。
Oncogene. 2012 Jun 21;31(25):3023-38. doi: 10.1038/onc.2011.478. Epub 2011 Oct 17.